Ha Tay Pharmaceutical JSC (HNX:DHT)
Vietnam · Delayed Price · Currency is VND 69,500
-500 (-0.71%)
At close: Feb 2, 2026
Ha Tay Pharmaceutical JSC Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Jan '21 Jan 1, 2021 |
| 2,251,584 | 2,086,353 | 1,999,304 | 1,837,395 | 1,609,364 | 2,006,475 | |
Revenue Growth (YoY) | 11.57% | 4.35% | 8.81% | 14.17% | -19.79% | -1.75% |
Cost of Revenue | 2,031,607 | 1,866,534 | 1,795,972 | 1,650,138 | 1,455,342 | 1,767,422 |
Gross Profit | 219,976 | 219,818 | 203,331 | 187,256 | 154,022 | 239,053 |
Selling, General & Admin | 160,377 | 143,306 | 104,115 | 84,806 | 91,953 | 129,633 |
Operating Expenses | 160,377 | 143,306 | 104,115 | 84,806 | 91,953 | 129,633 |
Operating Income | 59,599 | 76,513 | 99,216 | 102,450 | 62,070 | 109,420 |
Interest Expense | -14,088 | -13,449 | -20,099 | -14,304 | -13,993 | -13,323 |
Interest & Investment Income | 26,764 | 19,544 | 19,614 | 25,120 | 29,451 | 12,999 |
Earnings From Equity Investments | 9,394 | 6,756 | 4,171 | 2,971 | 1,996 | 1,363 |
Currency Exchange Gain (Loss) | - | - | - | - | 277.88 | -2,838 |
Other Non Operating Income (Expenses) | 5,383 | 5,858 | 7,442 | 6,986 | 9,788 | 12,519 |
EBT Excluding Unusual Items | 87,052 | 95,222 | 110,344 | 123,224 | 89,590 | 120,140 |
Gain (Loss) on Sale of Assets | - | - | - | - | -77.14 | 396.34 |
Pretax Income | 87,052 | 95,222 | 110,344 | 123,224 | 89,513 | 120,536 |
Income Tax Expense | 17,853 | 20,028 | 21,382 | 24,259 | 18,123 | 24,427 |
Earnings From Continuing Operations | 69,199 | 75,194 | 88,961 | 98,964 | 71,390 | 96,109 |
Minority Interest in Earnings | -2,629 | -3,422 | -3,906 | -3,753 | -3,444 | -4,061 |
Net Income | 66,570 | 71,772 | 85,056 | 95,211 | 67,946 | 92,047 |
Net Income to Common | 66,570 | 71,772 | 85,056 | 95,211 | 67,946 | 92,047 |
Net Income Growth | -2.50% | -15.62% | -10.67% | 40.13% | -26.18% | 6.74% |
Shares Outstanding (Basic) | 91 | 91 | 56 | - | 81 | 65 |
Shares Outstanding (Diluted) | 91 | 91 | 56 | - | 81 | 81 |
Shares Change (YoY) | - | 62.83% | - | - | -0.77% | - |
EPS (Basic) | 734.97 | 792.41 | 1529.08 | - | 841.84 | 1414.64 |
EPS (Diluted) | 734.97 | 792.41 | 1529.08 | - | 841.84 | 1131.71 |
EPS Growth | - | -48.18% | - | - | -25.61% | - |
Free Cash Flow | 52,238 | -115,173 | -95,725 | -286,024 | -83,817 | 5,676 |
Free Cash Flow Per Share | 576.74 | -1271.59 | -1720.88 | - | -1038.49 | 69.79 |
Dividend Per Share | - | - | - | - | 324.675 | - |
Gross Margin | 9.77% | 10.54% | 10.17% | 10.19% | 9.57% | 11.91% |
Operating Margin | 2.65% | 3.67% | 4.96% | 5.58% | 3.86% | 5.45% |
Profit Margin | 2.96% | 3.44% | 4.25% | 5.18% | 4.22% | 4.59% |
Free Cash Flow Margin | 2.32% | -5.52% | -4.79% | -15.57% | -5.21% | 0.28% |
EBITDA | 80,881 | 96,993 | 116,294 | 119,898 | 78,504 | 122,680 |
EBITDA Margin | 3.59% | 4.65% | 5.82% | 6.53% | 4.88% | 6.11% |
D&A For EBITDA | 21,282 | 20,481 | 17,078 | 17,448 | 16,435 | 13,259 |
EBIT | 59,599 | 76,513 | 99,216 | 102,450 | 62,070 | 109,420 |
EBIT Margin | 2.65% | 3.67% | 4.96% | 5.58% | 3.86% | 5.45% |
Effective Tax Rate | 20.51% | 21.03% | 19.38% | 19.69% | 20.25% | 20.27% |
Revenue as Reported | 2,251,584 | 2,086,353 | 1,999,304 | 1,837,395 | 1,609,364 | 2,006,475 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.